Aclaris Therapeutics Inc.

17.65-0.3500-1.94%Vol 441.15K1Y Perf 23.29%
Aug 9th, 2022 16:00 DELAYED
BID15.40 ASK19.00
Open17.94 Previous Close18.00
Pre-Market- After-Market17.65
 - -  - -%
Target Price
34.80 
Analyst Rating
Strong Buy 1.00
Potential %
97.17 
Finscreener Ranking
★★★★     53.60
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     55.00
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     49.91
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
78.34 
Earnings Rating
Strong Buy
Market Cap1.18B 
Earnings Date
4th Aug 2022
Alpha0.03 Standard Deviation0.37
Beta0.61 

Today's Price Range

17.4618.37

52W Range

9.2619.97

5 Year PE Ratio Range

-9.40-2.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
26.76%
1 Month
10.16%
3 Months
61.43%
6 Months
41.29%
1 Year
23.29%
3 Years
1 900.00%
5 Years
-33.26%
10 Years
-

TickerPriceChg.Chg.%
ACRS17.65-0.3500-1.94
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
15.40
-1 140.30
-1 127.20
-2 098.60
-
RevenueValueIndustryS&P 500US Markets
4.61M
0.07
-22.75
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.36-0.3113.89
Q01 2022-0.39-0.3120.51
Q04 2021-0.36-0.37-2.78
Q03 2021-0.27-0.35-29.63
Q02 2021-0.26-0.34-30.77
Q01 2021-0.27-0.57-111.11
Q04 2020-0.28-0.31-10.71
Q03 2020-0.29-0.2513.79
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.3618.18Positive
9/2022 QR-0.3819.15Positive
12/2022 FY-1.4919.02Positive
12/2023 FY-1.4616.57Positive
Next Report Date-
Estimated EPS Next Report-0.36
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume441.15K
Shares Outstanding66.67K
Shares Float64.17M
Trades Count6.68K
Dollar Volume7.83M
Avg. Volume316.20K
Avg. Weekly Volume330.53K
Avg. Monthly Volume248.14K
Avg. Quarterly Volume369.92K

Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 18 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 457.51K shares and market capitalization of 1.18B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.

The one-year performance of Aclaris Therapeutics Inc. stock is 23.29%, while year-to-date (YTD) performance is 23.8%. ACRS stock has a five-year performance of -33.26%. Its 52-week range is between 9.26 and 19.97, which gives ACRS stock a 52-week price range ratio of 78.34%

Aclaris Therapeutics Inc. currently has a PE ratio of -11.10, a price-to-book (PB) ratio of 5.63, a price-to-sale (PS) ratio of 217.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -42.70%, a ROC of -55.07% and a ROE of -56.53%. The company’s profit margin is -%, its EBITDA margin is -1 127.20%, and its revenue ttm is $4.61 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Aclaris Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Strong Buy (1), with a target price of $34.8, which is +97.17% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aclaris Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 30.39, ATR14 : 1.23, CCI20 : 264.01, Chaikin Money Flow : 0.15, MACD : 0.45, Money Flow Index : 53.23, ROC : 13.21, RSI : 52.10, STOCH (14,3) : 88.57, STOCH RSI : 1.00, UO : 62.88, Williams %R : -11.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $0), Andrew Kenneth Williams Powell (Option Excercise at a value of $0), Andrew N. Schiff (Option Excercise at a value of $0), Andrew N. Schiff (Sold 19 565 shares of value $296 269 ), Bryan M. Reasons (Option Excercise at a value of $0), Christopher Molineaux (Option Excercise at a value of $0), Frank Ruffo (Option Excercise at a value of $0), Frank Ruffo (Sold 12 823 shares of value $199 335 ), Joseph Monahan (Option Excercise at a value of $0), Joseph Monahan (Sold 57 165 shares of value $915 101 ), Kamil Ali-Jackson (Option Excercise at a value of $0), Maxine Gowen (Option Excercise at a value of $0), Neal Walker (Option Excercise at a value of $0), Neal Walker (Sold 126 303 shares of value $1 956 746 ), Vincent J. Milano (Option Excercise at a value of $0), William D. Humphries (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.

CEO: Neal Walker

Telephone: +1 484 324-7933

Address: 640 Lee Road, Wayne 19087, PA, US

Number of employees: 60

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

69%31%

Bearish Bullish

63%37%

Bearish Bullish

63%38%


News

Stocktwits